Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Degraded neutrophil extracellular traps promote the growth of Actinobacillus pleuropneumoniae.

de Buhr N, Bonilla MC, Pfeiffer J, Akhdar S, Schwennen C, Kahl BC, Waldmann KH, Valentin-Weigand P, Hennig-Pauka I, von Köckritz-Blickwede M.

Cell Death Dis. 2019 Sep 10;10(9):657. doi: 10.1038/s41419-019-1895-4.

2.

A retrospective analysis of the pathogens in the airways of patients with primary ciliary dyskinesia.

Roden L, Görlich D, Omran H, Peters G, Große-Onnebrink J, Kahl BC.

Respir Med. 2019 Sep;156:69-77. doi: 10.1016/j.rmed.2019.08.009. Epub 2019 Aug 15.

PMID:
31437650
3.

Interference with Pseudomonas aeruginosa quorum sensing and virulence by the mycobacterial PQS dioxygenase AqdC in combination with the N-acylhomoserine lactone lactonase QsdA.

Birmes FS, Säring R, Hauke MC, Ritzmann NH, Drees SL, Daniel J, Treffon J, Liebau E, Kahl BC, Fetzner S.

Infect Immun. 2019 Jul 15. pii: IAI.00278-19. doi: 10.1128/IAI.00278-19. [Epub ahead of print]

PMID:
31308081
4.

Phenotypic and Genotypic Characterization of Escherichia coli Causing Urinary Tract Infections in Kidney-Transplanted Patients.

Abo Basha J, Kiel M, Görlich D, Schütte-Nütgen K, Witten A, Pavenstädt H, Kahl BC, Dobrindt U, Reuter S.

J Clin Med. 2019 Jul 7;8(7). pii: E988. doi: 10.3390/jcm8070988.

5.

The prevalence of Staphylococcus aureus with mucoid phenotype in the airways of patients with cystic fibrosis-A prospective study.

Lennartz FE, Schwartbeck B, Dübbers A, Große-Onnebrink J, Kessler C, Küster P, Schültingkemper H, Peters G, Kahl BC.

Int J Med Microbiol. 2019 Jul;309(5):283-287. doi: 10.1016/j.ijmm.2019.05.002. Epub 2019 May 11.

PMID:
31122879
6.

In vivo competition and horizontal gene transfer among distinct Staphylococcus aureus lineages as major drivers for adaptational changes during long-term persistence in humans.

Langhanki L, Berger P, Treffon J, Catania F, Kahl BC, Mellmann A.

BMC Microbiol. 2018 Oct 22;18(1):152. doi: 10.1186/s12866-018-1308-3.

7.

Personal microbiological consultations improve the therapeutic management of Staphylococcus aureus bacteremia.

Kampmeier S, Correa-Martinez CL, Peters G, Mellmann A, Kahl BC.

J Infect. 2018 Oct;77(4):349-356. doi: 10.1016/j.jinf.2018.07.011. Epub 2018 Jul 29. No abstract available.

PMID:
30067944
8.

Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study.

Schwerdt M, Neumann C, Schwartbeck B, Kampmeier S, Herzog S, Görlich D, Dübbers A, Große-Onnebrink J, Kessler C, Küster P, Schültingkemper H, Treffon J, Peters G, Kahl BC.

Int J Med Microbiol. 2018 Aug;308(6):631-639. doi: 10.1016/j.ijmm.2018.02.003. Epub 2018 Feb 24.

PMID:
29501453
9.

Adaptation of Staphylococcus aureus to Airway Environments in Patients With Cystic Fibrosis by Upregulation of Superoxide Dismutase M and Iron-Scavenging Proteins.

Treffon J, Block D, Moche M, Reiss S, Fuchs S, Engelmann S, Becher D, Langhanki L, Mellmann A, Peters G, Kahl BC.

J Infect Dis. 2018 Apr 11;217(9):1453-1461. doi: 10.1093/infdis/jiy012.

PMID:
29325044
10.

Staphylococcus aureus and Pseudomonas aeruginosa Respiratory Tract Coinfection-What Can We Learn From Animal Models?

Kahl BC.

J Infect Dis. 2018 Mar 5;217(6):854-856. doi: 10.1093/infdis/jix624. No abstract available.

PMID:
29216374
11.

Male kidney allograft recipients at risk for urinary tract infection?

Thölking G, Schuette-Nuetgen K, Vogl T, Dobrindt U, Kahl BC, Brand M, Pavenstädt H, Suwelack B, Koch R, Reuter S.

PLoS One. 2017 Nov 16;12(11):e0188262. doi: 10.1371/journal.pone.0188262. eCollection 2017.

12.

Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients.

Mustafa MH, Khandekar S, Tunney MM, Elborn JS, Kahl BC, Denis O, Plésiat P, Traore H, Tulkens PM, Vanderbist F, Van Bambeke F.

Eur Respir J. 2017 May 19;49(5). pii: 1601847. doi: 10.1183/13993003.01847-2016. Print 2017 May.

13.

Reduced Immunoglobulin (Ig) G Response to Staphylococcus aureus in STAT3 Hyper-IgE Syndrome.

Stentzel S, Hagl B, Abel F, Kahl BC, Rack-Hoch A, Bröker BM, Renner ED.

Clin Infect Dis. 2017 May 1;64(9):1279-1282. doi: 10.1093/cid/cix140.

PMID:
28203787
14.

High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations.

Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, Denis O, Kahl BC, Tulkens PM, Van Bambeke F.

Int J Antimicrob Agents. 2016 Dec;48(6):740-743. doi: 10.1016/j.ijantimicag.2016.09.012. Epub 2016 Oct 19.

PMID:
28128097
15.

Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.

Chalhoub H, Pletzer D, Weingart H, Braun Y, Tunney MM, Elborn JS, Rodriguez-Villalobos H, Plésiat P, Kahl BC, Denis O, Winterhalter M, Tulkens PM, Van Bambeke F.

Sci Rep. 2017 Jan 16;7:40208. doi: 10.1038/srep40208.

16.

Dynamic in vivo mutations within the ica operon during persistence of Staphylococcus aureus in the airways of cystic fibrosis patients.

Schwartbeck B, Birtel J, Treffon J, Langhanki L, Mellmann A, Kale D, Kahl J, Hirschhausen N, Neumann C, Lee JC, Götz F, Rohde H, Henke H, Küster P, Peters G, Kahl BC.

PLoS Pathog. 2016 Nov 30;12(11):e1006024. doi: 10.1371/journal.ppat.1006024. eCollection 2016 Nov.

17.

Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.

Junge S, Görlich D, den Reijer M, Wiedemann B, Tümmler B, Ellemunter H, Dübbers A, Küster P, Ballmann M, Koerner-Rettberg C, Große-Onnebrink J, Heuer E, Sextro W, Mainz JG, Hammermann J, Riethmüller J, Graepler-Mainka U, Staab D, Wollschläger B, Szczepanski R, Schuster A, Tegtmeyer FK, Sutharsan S, Wald A, Nofer JR, van Wamel W, Becker K, Peters G, Kahl BC.

PLoS One. 2016 Nov 18;11(11):e0166220. doi: 10.1371/journal.pone.0166220. eCollection 2016.

18.

Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Mustafa MH, Chalhoub H, Denis O, Deplano A, Vergison A, Rodriguez-Villalobos H, Tunney MM, Elborn JS, Kahl BC, Traore H, Vanderbist F, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6735-6741. doi: 10.1128/AAC.01046-16. Print 2016 Nov.

19.

Lack of Sphingosine Causes Susceptibility to Pulmonary Staphylococcus Aureus Infections in Cystic Fibrosis.

Tavakoli Tabazavareh S, Seitz A, Jernigan P, Sehl C, Keitsch S, Lang S, Kahl BC, Edwards M, Grassmé H, Gulbins E, Becker KA.

Cell Physiol Biochem. 2016;38(6):2094-102. doi: 10.1159/000445567. Epub 2016 May 17.

20.

Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Kahl BC, Becker K, Löffler B.

Clin Microbiol Rev. 2016 Apr;29(2):401-27. doi: 10.1128/CMR.00069-15. Review.

21.

Chromosomally and Extrachromosomally Mediated High-Level Gentamicin Resistance in Streptococcus agalactiae.

Sendi P, Furitsch M, Mauerer S, Florindo C, Kahl BC, Shabayek S, Berner R, Spellerberg B.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1702-7. doi: 10.1128/AAC.01933-15.

22.

The clinical impact of livestock-associated methicillin-resistant Staphylococcus aureus of the clonal complex 398 for humans.

Becker K, Ballhausen B, Kahl BC, Köck R.

Vet Microbiol. 2017 Feb;200:33-38. doi: 10.1016/j.vetmic.2015.11.013. Epub 2015 Nov 22.

PMID:
26644311
23.

Thymidine-Dependent Staphylococcus aureus Small-Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have Increased Fitness during SXT Challenge.

Kriegeskorte A, Lorè NI, Bragonzi A, Riva C, Kelkenberg M, Becker K, Proctor RA, Peters G, Kahl BC.

Antimicrob Agents Chemother. 2015 Dec;59(12):7265-72. doi: 10.1128/AAC.00742-15. Epub 2015 Sep 14.

24.

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade.

Raidt L, Idelevich EA, Dübbers A, Küster P, Drevinek P, Peters G, Kahl BC.

Pediatr Infect Dis J. 2015 Jul;34(7):700-5. doi: 10.1097/INF.0000000000000714.

PMID:
25851069
25.
26.

Microarray-based identification of human antibodies against Staphylococcus aureus antigens.

Kloppot P, Selle M, Kohler C, Stentzel S, Fuchs S, Liebscher V, Müller E, Kale D, Ohlsen K, Bröker BM, Zipfel PF, Kahl BC, Ehricht R, Hecker M, Engelmann S.

Proteomics Clin Appl. 2015 Dec;9(11-12):1003-11. doi: 10.1002/prca.201400123. Epub 2015 Apr 1.

PMID:
25676254
27.

Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.

Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, Kahl BC, Van Bambeke F, Tulkens PM.

J Antimicrob Chemother. 2015 May;70(5):1596-8. doi: 10.1093/jac/dku551. Epub 2015 Jan 14. No abstract available.

PMID:
25587996
28.

Transcriptional adaptations during long-term persistence of Staphylococcus aureus in the airways of a cystic fibrosis patient.

Windmüller N, Witten A, Block D, Bunk B, Spröer C, Kahl BC, Mellmann A.

Int J Med Microbiol. 2015 Jan;305(1):38-46. doi: 10.1016/j.ijmm.2014.10.005. Epub 2014 Oct 29.

29.

Staphylococcus aureus small colony variants show common metabolic features in central metabolism irrespective of the underlying auxotrophism.

Kriegeskorte A, Grubmüller S, Huber C, Kahl BC, von Eiff C, Proctor RA, Peters G, Eisenreich W, Becker K.

Front Cell Infect Microbiol. 2014 Oct 21;4:141. doi: 10.3389/fcimb.2014.00141. eCollection 2014.

30.

Staphylococcus aureus Small Colony Variants (SCVs): a road map for the metabolic pathways involved in persistent infections.

Proctor RA, Kriegeskorte A, Kahl BC, Becker K, Löffler B, Peters G.

Front Cell Infect Microbiol. 2014 Jul 28;4:99. doi: 10.3389/fcimb.2014.00099. eCollection 2014. Review.

31.

Inactivation of thyA in Staphylococcus aureus attenuates virulence and has a strong impact on metabolism and virulence gene expression.

Kriegeskorte A, Block D, Drescher M, Windmüller N, Mellmann A, Baum C, Neumann C, Lorè NI, Bragonzi A, Liebau E, Hertel P, Seggewiss J, Becker K, Proctor RA, Peters G, Kahl BC.

MBio. 2014 Jul 29;5(4):e01447-14. doi: 10.1128/mBio.01447-14.

32.

Prevalence and persistence of Escherichia coli in the airways of cystic fibrosis patients - an unrecognized CF pathogen?

Barillova P, Tchesnokova V, Dübbers A, Küster P, Peters G, Dobrindt U, Sokurenko EV, Kahl BC.

Int J Med Microbiol. 2014 May;304(3-4):415-21. doi: 10.1016/j.ijmm.2014.02.008. Epub 2014 Feb 19.

PMID:
24630795
33.

Assessment of microbiological diagnostic procedures for respiratory specimens from cystic fibrosis patients in German laboratories by use of a questionnaire.

Häfner L, Peters G, Kahl BC.

J Clin Microbiol. 2014 Mar;52(3):977-9. doi: 10.1128/JCM.02866-13. Epub 2014 Jan 3.

34.

Acapsular clinical Staphylococcus aureus isolates lack agr function.

Fischer J, Lee JC, Peters G, Kahl BC.

Clin Microbiol Infect. 2014 Jul;20(7):O414-7. doi: 10.1111/1469-0691.12429. Epub 2013 Nov 14.

35.

Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation.

Hirschhausen N, Block D, Bianconi I, Bragonzi A, Birtel J, Lee JC, Dübbers A, Küster P, Kahl J, Peters G, Kahl BC.

Int J Med Microbiol. 2013 Dec;303(8):685-92. doi: 10.1016/j.ijmm.2013.09.012. Epub 2013 Oct 8.

PMID:
24183484
36.

Intravenous antibiotics given for 2 weeks do not eradicate persistent Staphylococcus aureus clones in cystic fibrosis patients.

Andersen C, Kahl BC, Olesen HV, Jensen-Fangel S, Nørskov-Lauritsen N.

Clin Microbiol Infect. 2014 May;20(5):O285-91. doi: 10.1111/1469-0691.12406. Epub 2013 Nov 4.

37.

Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa.

Alabi AS, Frielinghaus L, Kaba H, Kösters K, Huson MA, Kahl BC, Peters G, Grobusch MP, Issifou S, Kremsner PG, Schaumburg F.

BMC Infect Dis. 2013 Oct 2;13:455. doi: 10.1186/1471-2334-13-455.

38.

Small colony variants (SCVs) of Staphylococcus aureus--a bacterial survival strategy.

Kahl BC.

Infect Genet Evol. 2014 Jan;21:515-22. doi: 10.1016/j.meegid.2013.05.016. Epub 2013 May 27. Review.

PMID:
23722021
39.

Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data.

Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2013 Jul;68(7):1455-64. doi: 10.1093/jac/dkt072. Epub 2013 Mar 13. Review.

PMID:
23485724
40.

Intracellular forms of menadione-dependent small-colony variants of methicillin-resistant Staphylococcus aureus are hypersusceptible to β-lactams in a THP-1 cell model due to cooperation between vacuolar acidic pH and oxidant species.

Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Tulkens PM, Van Bambeke F.

J Antimicrob Chemother. 2012 Dec;67(12):2873-81. doi: 10.1093/jac/dks325. Epub 2012 Sep 21.

PMID:
23002174
41.
42.

Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.

Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, Tulkens PM, Van Bambeke F.

Antimicrob Agents Chemother. 2012 Jul;56(7):3700-11. doi: 10.1128/AAC.00285-12. Epub 2012 May 7.

43.

The length of the Staphylococcus aureus protein A polymorphic region regulates inflammation: impact on acute and chronic infection.

Garofalo A, Giai C, Lattar S, Gardella N, Mollerach M, Kahl BC, Becker K, Prince AS, Sordelli DO, Gómez MI.

J Infect Dis. 2012 Jul 1;206(1):81-90. doi: 10.1093/infdis/jis311. Epub 2012 Apr 25.

PMID:
22535996
44.

Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.

Idelevich EA, Kriegeskorte A, Stubbings W, Kahl BC, Peters G, Becker K.

J Antimicrob Chemother. 2011 Dec;66(12):2809-13. doi: 10.1093/jac/dkr393. Epub 2011 Sep 21.

PMID:
21948963
45.

Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease.

Kahl BC.

Int J Med Microbiol. 2010 Dec;300(8):514-9. doi: 10.1016/j.ijmm.2010.08.002. Epub 2010 Sep 16. Review.

PMID:
20843739
46.

Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils.

Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G.

PLoS Pathog. 2010 Jan 8;6(1):e1000715. doi: 10.1371/journal.ppat.1000715.

47.

Non-spa-typeable clinical Staphylococcus aureus strains are naturally occurring protein A mutants.

Baum C, Haslinger-Löffler B, Westh H, Boye K, Peters G, Neumann C, Kahl BC.

J Clin Microbiol. 2009 Nov;47(11):3624-9. doi: 10.1128/JCM.00941-09. Epub 2009 Sep 16.

48.

Characterization of clinical Enterococcus faecalis small-colony variants.

Wellinghausen N, Chatterjee I, Berger A, Niederfuehr A, Proctor RA, Kahl BC.

J Clin Microbiol. 2009 Sep;47(9):2802-11. doi: 10.1128/JCM.00485-09. Epub 2009 Jul 15.

49.

Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis.

Mainz JG, Naehrlich L, Schien M, Käding M, Schiller I, Mayr S, Schneider G, Wiedemann B, Wiehlmann L, Cramer N, Pfister W, Kahl BC, Beck JF, Tümmler B.

Thorax. 2009 Jun;64(6):535-40. doi: 10.1136/thx.2008.104711. Epub 2009 Mar 11.

PMID:
19282318
50.

The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.

Besier S, Zander J, Kahl BC, Kraiczy P, Brade V, Wichelhaus TA.

Antimicrob Agents Chemother. 2008 Jun;52(6):2183-9. doi: 10.1128/AAC.01395-07. Epub 2008 Mar 31.

Supplemental Content

Support Center